Drug Profile
Research programme: eye disorder therapies - Bicycle Therapeutics/Oxurion
Alternative Names: TG-758Latest Information Update: 11 Sep 2018
Price :
$50
*
At a glance
- Originator Bicycle Therapeutics
- Developer Bicycle Therapeutics; ThromboGenics
- Class Eye disorder therapies; Peptides
- Mechanism of Action Capillary permeability modulators; Plasma kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetic macular oedema; Eye disorders
Most Recent Events
- 10 Sep 2018 Thrombogenics is now called Oxurion
- 01 Feb 2016 Discontinued - Preclinical for Diabetic macular oedema in Belgium (Ophthalmic)
- 01 Feb 2016 Discontinued - Preclinical for Diabetic macular oedema in United Kingdom (Ophthalmic)